Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00433771 · ClinicalTrials.gov registry record · Phase 3

A Study of the WallFlex™ Biliary Fully-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction

A Phase 3 study of Cholestasis, Extrahepatic, sponsored by Boston Scientific Corporation.

Completed
Registry status
Phase 3
Development phase
74
Enrollment target
10
Study locations

NCT00433771 is a Phase 3 study of Cholestasis, Extrahepatic that has completed, run by Boston Scientific Corporation. The registered enrollment target is 74 participants. The trial reports 10 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00433771, a Phase 3 study of Cholestasis, Extrahepatic, has completed, sponsored by Boston Scientific Corporation.

COMPLETED
Registry status
Phase 3
Development phase
74 participants
Enrollment target
10
Study locations

Study Summary

The overall objective of this study is to assess the functionality of the WallFlex™ Biliary Fully-covered stent as a palliative treatment for malignant bile duct obstruction.

Conditions Studied

Interventions

  • DEVICE WallFlex™ Biliary Fully Covered Metal Stent placement

Study Locations (10)

Minnesota

  • Hennepin County Medical Center - Minneapolis
  • Mayo Clinic - Rochester

California

  • California Pacific Medical Center - San Francisco

Colorado

  • Univ. of Colorado Health Sciences - Aurora

Missouri

  • Washington University School of Medicine - St Louis

North Carolina

  • Duke University Med Center - Durham

Pennsylvania

  • Thomas Jefferson University - Philadelphia

Texas

  • MD Anderson Cancer Center - Houston

Virginia

  • Univ. of VA Medical Center - Charlottesville

Trial Details

FieldValue
Enrollment Target 74 participants
Start Date 2007-03
Est. Completion 2008-05
Phase Phase 3

Sponsor

Boston Scientific Corporation

280 total trials

What the Registry Record Tells You About NCT00433771

The ClinicalTrials.gov registry entry for NCT00433771 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cholestasis, Extrahepatic appearing as the primary indexed condition, and to 1 intervention - of which WallFlex™ Biliary Fully Covered Metal Stent placement is the first listed.

NCT00433771 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Minnesota, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT00433771 about?

NCT00433771 is a clinical study titled "A Study of the WallFlex™ Biliary Fully-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction". The overall objective of this study is to assess the functionality of the WallFlex™ Biliary Fully-covered stent as a palliative treatment for malignant bile duct obstruction.

What is the current status of trial NCT00433771?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 74 participants. The study started on 2007-03. Estimated completion is 2008-05.

What conditions does trial NCT00433771 study?

This clinical trial studies the following conditions: Cholestasis, Extrahepatic.

What interventions are being tested in trial NCT00433771?

The interventions under investigation include: WallFlex™ Biliary Fully Covered Metal Stent placement (DEVICE).

Who is sponsoring clinical trial NCT00433771?

This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00433771 being conducted?

This trial has 10 study locations across California, Colorado, Minnesota, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.